echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The process of upgrading domestic pharmaceutical equipment has begun, and domestic substitution is coming

    The process of upgrading domestic pharmaceutical equipment has begun, and domestic substitution is coming

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical equipment refers to mechanical equipment
    used in pharmaceutical production, inspection, packaging and other process purposes.
    After decades of development, China's pharmaceutical equipment industry has grown into a number of pharmaceutical equipment manufacturers
    represented by Chutian Technology and Dongfulong, with strong research and development capabilities, independent intellectual property rights and strong competitiveness.

     
    The process of upgrading domestic pharmaceutical equipment has begun, and domestic substitution is coming (Image source: Pharmaceutical Network)
     
    At present, with the continuous enhancement of competitiveness, the revenue and net profit of many pharmaceutical equipment manufacturers are accelerating
    .
    It is understood that in the first half of 2022, the performance of many listed companies of pharmaceutical equipment has been red, among which Chutian Technology and Dongfulong have achieved revenue growth of more than 20%, and net profits have increased
    significantly.
    Specifically, Chutian Technology achieved revenue of about 2.
    871 billion yuan in the first half of the year, a year-on-year increase of 20.
    04%; The net profit was about 299 million yuan, a year-on-year increase of 26.
    74%.

    Dongfulong also achieved revenue of about 2.
    43 billion yuan in the first half of the year, a year-on-year increase of 34.
    11% against the trend; The net profit was about 400 million yuan, a year-on-year increase of 18.
    33%.


     
    It is worth noting that with the aging of the population, the continuous upgrading of consumption, the rapid development of the market such as biological drugs, innovative drugs and pharmaceutical outsourcing, the industry expects that comprehensive factors will continue to bring expansion momentum to the market demand for pharmaceutical equipment, by 2025, the scale of China's pharmaceutical equipment market will reach about 87.
    5 billion yuan (excluding consumables, auxiliary materials, etc.
    ), with a compound growth rate of about 10.
    22%
    from 2020 to 2025.
    In this context, related pharmaceutical equipment companies will undoubtedly usher in more benefits
    .
    However, it is not simple to seize the opportunity, and the industry believes that pharmaceutical machinery companies need to accelerate innovation and upgrading in order to expand more growth space
    .

     
    In fact, the current domestic pharmaceutical equipment upgrade process has begun, and domestic pharmaceutical equipment enterprises led by Chutian Technology and Dongfulong are continuing to expand and accelerate product performance and production capacity
    through R&D investment.
    It is reported that on July 13 this year, Dongfulong's 3.
    2 billion yuan directional additional issuance was approved, and market analysis said that this will increase the development potential of Dongfulong in capacity construction and process technology
    .

     
    In recent years, Canaan Technology has focused on automation, continuity, greening and intelligence, and is also accelerating innovation and upgrading
    .
    At present, Canaan Technology's solid preparation equipment is equipped with a self-developed set of adaptive, self-driving and self-adjusting SMART system
    .
    It is worth mentioning that in April, Canaan Science and Technology announced that it planned to invest 50 million yuan with its own funds to establish a wholly-owned subsidiary, Tianjin Canaan Biomedical Equipment Co.
    , Ltd.
    (hereinafter referred to as "Tianjin Canaan").

    According to the announcement, this foreign investment is an important part of the company's extension of the biopharmaceutical equipment industry chain, which is conducive to the horizontal expansion of its biopharmaceutical equipment and enhances the company's market competitiveness and sustainable profitability
    .

     
    It is understood that in order to open up the upstream and downstream expansion growth space, Canaan Technology also said that the future business focus will shift from production to service, and products will extend
    from pharmaceutical stand-alone machines to complete lines and overall solutions.
    At the same time, it will continue to be deeply involved in the entire life cycle of drugs, from front-end research and development to the final drug production
    .

     
    At present, the entire pharmaceutical equipment industry environment, including market demand, policies and other factors, as well as the rise of innovation, are bringing a new round of opportunities
    to leading enterprises.
    In order to better seize the opportunity, a large number of enterprises have also embarked on the process of accelerating upgrading, not only product performance and production capacity are increasing, but also product lines are becoming increasingly rich
    .
    The industry said that in the future, with the continuous acceleration of the upgrading of domestic pharmaceutical equipment, the import substitution process will continue to accelerate
    .

     
    This has actually been shown
    in the head performance.
    Chutian Technology mentioned in an institutional survey on August 28 that the company achieved good results in the first half of 2022, one of which was high-end import substitution
    .
    Canaan Technology also mentioned in the Chinese newspaper that some of the company's products have reached the international advanced level, among which the quality and performance of the core products have been improved year by year, similar to foreign advanced products, with the strength of import substitution, and the price is much lower than foreign imported equipment, meeting the multiple needs of customers for process accuracy, stable performance and economic cost, etc.
    , and has strong competitiveness
    in terms of cost performance.

     
    ={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js?cdnversion='+~(-new Date()/36e5)];
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.